Interaction of pain and chronic inflammation; [Wechselwirkungen von Schmerz und chronischer Entzündung]

被引:0
作者
Seifert O. [1 ]
Baerwald C. [1 ]
机构
[1] Klinik für Endokrinologie, Nephrologie und Rheumatologie, Universitätsklinikum Leipzig AöR, Liebigstr. 20, Leipzig
关键词
Central sensitization; Cytokines; Hyperalgesia; Neuroimmunomodulation; Rheumatic diseases;
D O I
10.1007/s00393-020-00951-8
中图分类号
学科分类号
摘要
Rheumatic diseases are characterized by chronic inflammation of synovial joints and are often associated with persistent pain and increased pain sensitivity. The inflammatory process is a complex cascade of events involving several mediators, which can lead to a chronic condition of pain. Inflammation can stimulate angiogenesis, and angiogenesis can facilitate inflammation. Inflammatory pain arises from tissue damage via the sensitization of pain receptors (nociceptors). The main peripheral mechanism underlying nociceptive pain is a change in the activity of the nociceptors located in the affected anatomical structures (joints, tendons, and ligaments), which renders them more sensitive to normally painful stimuli (hyperalgesia) or normally non-painful stimuli (allodynia). Neuroimmune interaction has been considered to play an essential role in rheumatic disease. Neurogenic inflammation, which influences normal central nervous system signaling, leads to insufficient signaling/bioavailability of various cytokines. These central mechanisms play an important role in the increased pain sensitivity following inflammation and are responsible for the development of secondary hyperalgesia in regions beyond the injured tissue. Reduction of pain in rheumatic disease requires familiarity with various pain mechanisms. © 2021, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码:205 / 213
页数:8
相关论文
共 30 条
  • [1] Ashraf S., Mapp P.I., Walsh D.A., Contributions of angiogenesis to inflammation, joint damage, and pain in a rat model of osteoarthritis, Arthritis Rheum, 63, 9, pp. 2700-2710, (2011)
  • [2] Bannwarth B., Kostine M., Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer?, Drugs, 77, 13, pp. 1377-1387, (2017)
  • [3] Bonnet C.S., Walsh D.A., Osteoarthritis, angiogenesis and inflammation, Rheumatology (Oxford), 44, 1, pp. 7-16, (2005)
  • [4] Cazzola M., Atzeni F., Boccassini L., Et al., Physiopathology of pain in rheumatology, Reumatismo, 66, 1, pp. 4-13, (2014)
  • [5] Crofford L.J., The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases, Endocrinol Metab Clin North Am, 31, 1, pp. 1-13, (2002)
  • [6] Culo M.I., Morovic-Vergles J., Etiology and pathogenesis of pain in rheumatic diseases, Reumatizam, 63, 1, pp. 18-22, (2016)
  • [7] Gatenholm B., Brittberg M., Neuropeptides: important regulators of joint homeostasis, Knee Surg Sports Traumatol Arthrosc, 27, 3, pp. 942-949, (2019)
  • [8] Grubb B.D., Activation of sensory neurons in the arthritic joint, Novartis Found Symp, 260, pp. 28-36, (2004)
  • [9] Handwerker H.O., Advancing our understanding of the mechanisms and mediators underlying pain and inflammation, Clin Drug Investig, 27, 1, pp. 1-6, (2007)
  • [10] Kojima M., Kojima T., Suzuki S., Et al., Depression, inflammation, and pain in patients with rheumatoid arthritis, Arthritis Rheum, 61, 8, pp. 1018-1024, (2009)